← Leaderboards
Alexander Niclas Freiberg
University Of Texas Med Br Galveston
$3,141,620
Attributed
$3,141,620
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $641.9K · FY2012–22$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,141,620 · 6
By mechanism
R21$1,900,654 · 5
R33$1,240,966 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Tetsuro Ikegami$3,820,605
- Joseph Frank Petrosino$10,625,598
- Alexander Bukreyev$20,278,136
- Kimberly Kershea Roberts$56,316
- Ian Maclachlan$4,986,074
Others in their field
Top investigators on “Virus Replication”
- Constance Ann Benson · University Of California, San Diego$187,673,896
- Judith S. Currier · University Of California Los Angeles$137,892,773
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Barton F Haynes · Duke University$110,672,613
- Charles M. Rice · Rockefeller University$53,754,576
- Rama Rao Amara · Emory University$53,347,944
Research focus
Virus ReplicationVirusVirus DiseasesIn VitroInfectionFamilyAnimal ModelAntiviral AgentsCellsAnti-Viral EfficacyImmuneNipah VirusPathway InteractionsAcutePathogenIn VivoNational Institute Of Allergy And Infectious DiseaseRna VirusesPublishingMolecularBunyaviridaeFda ApprovedTransmission ProcessParamyxoviridae
Grant awards (12)
Ebola virus infection of the female reproductive system$237,000
R21 · FY2022 · AI · contact PI
Therapeutic efficacy of favipiravir against henipavirus infections$200,000
R21 · FY2022 · AI · contact PI
Therapeutic efficacy of favipiravir against henipavirus infections$240,000
R21 · FY2021 · AI · contact PI
Ebola virus infection of the female reproductive system$197,500
R21 · FY2021 · AI · contact PI
Microphysiologic human organ cultures to study Nipah virus-induced lung pathology$197,500
R21 · FY2019 · AI · contact PI
Microphysiologic human organ cultures to study Nipah virus-induced lung pathology$236,500
R21 · FY2018 · AI · contact PI
Bioavailable proteasome inhibitors as broad-spectrum antivirals$415,893
R33 · FY2016 · AI · contact PI
Bioavailable proteasome inhibitors as broad-spectrum antivirals$409,384
R33 · FY2015 · AI · contact PI
Role of Reactive Oxygen Species in Nipah Virus Pathogenesis$232,500
R21 · FY2015 · AI · contact PI
Bioavailable proteasome inhibitors as broad-spectrum antivirals$415,689
R33 · FY2014 · AI · contact PI
Bioavailable proteasome inhibitors as broad-spectrum antivirals$125,694
R21 · FY2013 · AI · contact PI
Bioavailable proteasome inhibitors as broad-spectrum antivirals$233,960
R21 · FY2012 · AI · contact PI